Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
19.75 USD | -0.20% | -0.35% | -0.25% |
May. 16 | Scotiabank Adjusts Price Target on Healthpeak Properties to $23 From $22 | MT |
May. 16 | JPMorgan Adjusts Price Target on Healthpeak Properties to $21 From $19, Keeps Neutral Rating | MT |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
- The company's Refinitiv ESG score, based on a ranking of the company relative to its industry, comes out particularly well.
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- This company will be of major interest to investors in search of a high dividend stock.
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The opinion of analysts covering the stock has improved over the past four months.
Weaknesses
- The potential for earnings per share (EPS) growth in the coming years appears limited according to current analyst estimates.
- One of the major weak points of the company is its financial situation.
- With an expected P/E ratio at 53.5 and 37.59 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- The company's "enterprise value to sales" ratio is among the highest in the world.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Specialized REITs
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-0.25% | 13.9B | A | ||
+12.12% | 60.45B | A- | ||
-2.95% | 19.54B | A- | ||
+3.46% | 7.84B | B | ||
-7.31% | 6.05B | B- | ||
+14.43% | 3.64B | C- | ||
+0.84% | 3.33B | C+ | ||
+1.83% | 3B | C | ||
-6.05% | 3.09B | B+ | ||
+17.99% | 2.86B | C- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- DOC Stock
- Ratings Healthpeak Properties, Inc.